Explore the future of pyrogen testing – a critical step in ensuring the safety of injectable pharmaceuticals.
Pyrogens – fever-inducing substances from bacteria, fungi, or viruses – pose serious risks when present in pharmaceutical products. Traditional detection methods like the Rabbit Pyrogen Test (RPT) have been used for decades, but growing ethical concerns, limited sensitivity, and lack of quantification demand a more advanced solution.
Introducing the Monocyte Activation Test (MAT)
Recognised by the European Pharmacopoeia (Chapter 2.6.30) since 2010 and set to fully replace the RPT by July 1, 2025, the Monocyte Activation Test (MAT) offers a modern, animal-free, and highly sensitive alternative that mirrors the human immune response.
What You’ll Learn in This Webinar:
- The scientific foundation and regulatory recognition of MAT
- Insights into various MAT kit platforms and their performance
- Case studies from Eurofins BioPharma Product Testing Munich, including pre-commercial evaluations of next-gen MAT technologies
- Advantages of using reporter gene cell lines for faster results
- Practical guidance for transitioning to MAT ahead of regulatory deadlines
Why MAT is the Superior Choice:
- Sensitive, reproducible, and semi-quantitative results
- Detects both endotoxins and non-endotoxin pyrogens (NEPs)
- 100% animal-free and ethically aligned
- Supported by FDA, EMA, and other global regulatory bodies
Meet the speaker:
Dr. Nicole Rieth, Head of ATMP & Biologics Testing, Eurofins BioPharma Product Testing Munich GmbH
